title: Role of positron emission tomography/computed tomography findings for adjuvant chemotherapy indications in stage T1b-2aN0M0 lung adenocarcinoma.
abstract: BACKGROUND
  This study aimed to determine the significance of the maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) images on postoperative adjuvant chemotherapy for lung adenocarcinoma.
  
  
  METHODS
  We assessed recurrence-free interval (RFI) and overall survival (OS) based on SUVmax values derived from preoperative FDG-PET/CT images in 174 consecutive patients with completely resected pathologic stage T1b-2aN0M0 lung adenocarcinoma.
  
  
  RESULTS
  Ninety patients received adjuvant chemotherapy and 84 did not. Adjuvant chemotherapy conferred benefits on RFI and OS when compared with observation (p=0.007 and p=0.004, respectively). Multivariate Cox regression analyses revealed SUVmax as an independent prognostic factor for RFI. RFI and OS were significantly longer for patients who received adjuvant chemotherapy compared with those who did not in the group with SUVmax greater than or equal to 2.6 (p<0.001 and p<0.001, respectively). However, RFI and OS did not differ significantly between such patients in the group with SUVmax less than 2.6 (p=0.421 and p=0.452, respectively).
  
  
  CONCLUSIONS
  Preoperative SUVmax determined from FDG-PET/CT images reflected the effect of adjuvant chemotherapy after complete resection in patients with pathologic stage T1b-2aN0M0 lung adenocarcinoma. Indications for postoperative adjuvant chemotherapy among patients with lung adenocarcinoma might be more precisely determined using SUVmax derived from FDG-PET/CT images together with tumor size.
authors: Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
authors: Shinsuke
authors: S
authors: Sasada
authors: Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
authors: Yoshihiro
authors: Y
authors: Miyata
authors: Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
authors: Norifumi
authors: N
authors: Tsubokawa
authors: Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
authors: Takahiro
authors: T
authors: Mimae
authors: Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
authors: Tomoharu
authors: T
authors: Yoshiya
authors: Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. Electronic address: morihito@hiroshima-u.ac.jp.
authors: Morihito
authors: M
authors: Okada
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000601:surgery; D000077192:Adenocarcinoma of Lung; D000368:Aged; D017024:Chemotherapy, Adjuvant; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18